Please login to the form below

Not currently logged in
Email:
Password:

AZ and Medimmune bolsters immuno-oncology leadership

Dr Jean-Charles Soria and Dr Geoffrey Kim join the company

AstraZeneca and its global biologics research and development arm MedImmune, has appointed Dr Geoffrey Kim and Dr Jean-Charles Soria, respectively.

Kim and his team will focus on the development of the company’s late-stage immuno-oncology combinations programme, aiming to develop combination regimens that will deliver innovative medicines to patients.

He most recently served the US Food and Drug Administration (FDA) as its director, division of oncology products in the office of haematology oncology products since 2015 and also had roles at the National Cancer Institute (NCI).

Soria also taking up a leadership role within AZ’s global biologics research and development arm MedImmune, will lead a team responsible for the group’s strategy, growth, and advancement of the early oncology biologics portfolio.

Prior to joining MedImmune, he served as a professor of medicine and medical oncology at South-Paris University and has also served as chair of the drug development department at the Institut Gustave Roussy - a leading cancer-research institute.

He will join the company in early September succeeding Dr David Berman, who has been appointed to the new role of senior vice president, immuno-oncology franchise.

8th August 2017

From: Sales

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
EPG Health

REACH, ENGAGE & MEASURE - Accomplish meaningful HCP engagement via Medthority, our trusted independent medical website. Support education and treatment...

Latest intelligence

What’s in it for me? How to engage, motivate and support staff with internal training at OPEN Health
...
Environmental impact of in-person vs. virtual meetings
Although it will be tempting to resume in-person activities in the same capacity as before, we need to weigh the pros and cons of virtual vs. in-person vs. hybrid events...
US biosimilars
The US celebrates five years of biosimilars on the market – a look to the past, present and future
Why the success of biosimilars in the US has been mixed...

Infographics